Holen Sie sich die Stockscreener-App
1.36
2.86%
-0.04
Vorhandelsmarkt:
1.37
0.01
+0.74%
Schlusskurs vom Vortag:
$1.40
Offen:
$1.37
24-Stunden-Volumen:
2.40M
Relative Volume:
0.74
Marktkapitalisierung:
$364.32M
Einnahmen:
$236.20M
Nettoeinkommen (Verlust:
$-5.35M
KGV:
-75.98
EPS:
-0.0179
Netto-Cashflow:
$67.70M
1W Leistung:
-8.72%
1M Leistung:
+9.68%
6M Leistung:
-50.90%
1J Leistung:
-33.33%
1-Tages-Spanne:
$1.33
$1.40
1-Wochen-Bereich:
$1.33
$1.515
52-Wochen-Spanne:
$1.14
$4.0787
Akebia Therapeutics Inc Stock (AKBA) Company Profile
Firmenname
Akebia Therapeutics Inc
Sektor
Telefon
617-871-2098
Adresse
245 FIRST STREET, CAMBRIDGE, MA
Compare AKBA vs TAK, ZTS, HLN, TEVA, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AKBA
Akebia Therapeutics Inc
|
1.36 | 364.32M | 236.20M | -5.35M | 67.70M | -0.0179 |
TAK
Takeda Pharmaceutical Co Adr
|
18.04 | 56.99B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
115.93 | 48.94B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.70 | 43.30B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.14 | 33.94B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
531.82 | 23.31B | 3.18B | 1.33B | 1.04B | 27.90 |
Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-04 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-04-28 | Eingeleitet | Leerink Partners | Outperform |
| 2025-04-01 | Eingeleitet | Jefferies | Buy |
| 2023-11-29 | Fortgesetzt | BTIG Research | Buy |
| 2023-08-28 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2023-05-31 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-03-31 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2022-03-31 | Herabstufung | Mizuho | Buy → Neutral |
| 2022-03-31 | Herabstufung | Needham | Buy → Hold |
| 2022-03-31 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-03-08 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-01-29 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2019-11-14 | Bestätigt | Needham | Buy |
| 2019-08-06 | Bestätigt | H.C. Wainwright | Buy |
| 2019-07-11 | Bestätigt | H.C. Wainwright | Buy |
| 2019-05-02 | Eingeleitet | JP Morgan | Overweight |
| 2019-03-20 | Eingeleitet | Citigroup | Neutral |
| 2018-09-07 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2018-08-10 | Bestätigt | Needham | Buy |
| 2018-06-06 | Bestätigt | H.C. Wainwright | Buy |
| 2017-12-19 | Eingeleitet | Piper Jaffray | Overweight |
| 2017-12-07 | Eingeleitet | BTIG Research | Buy |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2017-07-10 | Bestätigt | H.C. Wainwright | Buy |
| 2017-04-27 | Bestätigt | H.C. Wainwright | Buy |
| 2017-04-27 | Bestätigt | Needham | Buy |
| 2016-12-27 | Bestätigt | H.C. Wainwright | Buy |
| 2016-12-20 | Bestätigt | JMP Securities | Mkt Outperform |
| 2016-11-15 | Eingeleitet | Aegis Capital | Buy |
| 2016-09-29 | Eingeleitet | Brean Capital | Buy |
| 2016-03-16 | Bestätigt | Needham | Buy |
| 2016-01-21 | Eingeleitet | Credit Suisse | Neutral |
Alle ansehen
Akebia Therapeutics Inc Aktie (AKBA) Neueste Nachrichten
Is the options market predicting a spike in Akebia Therapeutics stock? - MSN
Downgrade Watch: Should I invest in Akebia Therapeutics Inc before earnings2026 Performance Recap & Capital Efficiency Focused Ideas - baoquankhu1.vn
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Akebia Therapeutics, Inc. v. FibroGen, Inc. - Law.com
Trend Report: What is the earnings history of Akebia Therapeutics IncRecession Risk & Real-Time Buy Zone Alerts - baoquankhu1.vn
AKBA SEC FilingsAkebia Therapeut 10-K, 10-Q, 8-K Forms - Stock Titan
Akebia Therapeutics to Host Virtual R&D Day Highlighting Robust Kidney Disease Pipeline, on April 2, 2026 - The Manila Times
Is the Options Market Signaling a Surge in Akebia Therapeutics Shares? - Bitget
Is the Options Market Predicting a Spike in Akebia Therapeutics Stock? - Yahoo Finance
Akebia Therapeutics (NASDAQ:AKBA) Stock Crosses Below Two Hundred Day Moving AverageTime to Sell? - MarketBeat
Akebia Q2 2025 Earnings Preview - MSN
AKBA Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Akebia Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights - GuruFocus
Akebia Therapeutics, Inc. (AKBA) Shareholders Greenlight 18.9 Million Share Increase - MSN
Akebia Therapeutics Details Vafseo Commercial Push, TIW Dosing Plans and Kidney Pipeline at Leerink Conference - MarketBeat
Akebia Therapeutics Earnings Call: Vafseo Drives Growth - The Globe and Mail
Akebia at Leerink Conference: Strategic Focus on Vafseo and Pipeline By Investing.com - Investing.com Canada
Akebia Therapeutics expands portfolio beyond anemia with new rare kidney disease pipeline centered on AKB-097 and praliciguat - MSN
How The Akebia Therapeutics (AKBA) Story Is Shifting As Vafseo Revenue Assumptions Reset - Yahoo Finance
Akebia tops Q4 revenue expectations as Vafseo momentum strengthens outlook - MSN
Piper Sandler lowers Akebia Therapeutics (AKBA) PT to $4 as firm updates estimates following year-end reports - MSN
Akebia Therapeutics Stock Slumps After FDA Meeting Ends Without Path Forward for Vafseo Label Expansion - MSN
Akebia Therapeutics (NASDAQ:AKBA) CEO John Butler Purchases 69,270 Shares - MarketBeat
Layoff Watch: Does Akebia Therapeutics Inc offer margin of safety2025 Fundamental Recap & Safe Entry Zone Tips - baoquankhu1.vn
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Short Interest Update - MarketBeat
Citigroup Inc. Has $5.23 Million Position in Akebia Therapeutics, Inc. $AKBA - MarketBeat
Akebia Therapeutics to Present at the Leerink Partners 2026 Global Healthcare Conference - The Globe and Mail
Akebia Therapeutics CEO to speak at Miami Leerink 2026 healthcare forum - Stock Titan
Akebia Therapeutics Reports Inducement Grants - National Today
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
AKBA Shares Rise On Clinical Pipeline Optimism As Anemia Drug Gains Traction - Stocktwits
Analysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (CRNX), QuidelOrtho (QDEL) and Akebia Therapeutics (AKBA) - The Globe and Mail
Akebia Therapeutics (NASDAQ:AKBA) Lowered to "Strong Sell" Rating by Zacks Research - MarketBeat
Wall Street Zen Downgrades Akebia Therapeutics (NASDAQ:AKBA) to Hold - MarketBeat
Akebia Therapeutics, Inc. (AKBA) Stock Analysis: A Potential 233% Upside in the Healthcare Sector - DirectorsTalk Interviews
Akebia Therapeutics, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q4 2025 Earnings Call Transcript - Insider Monkey
Akebia Therapeutics (AKBA) Loss In Q4 2025 Tests Bullish Margin Narratives - simplywall.st
Akebia Therapeutics Inc (AKBA) Q4 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Challenges - GuruFocus
Akebia Therapeutics, Inc. posts full year 2025 financial results amid commercial and pipeline expansion - Traders Union
Key facts: Akebia Therapeutics reports 47% revenue rise; Phase 2 trials planned - TradingView
Akebia (AKBA) Q4 2025 Earnings Call Transcript - AOL.com
Akebia Therapeutics (NASDAQ:AKBA) Releases Earnings Results, Misses Expectations By $0.02 EPS - MarketBeat
Akebia Therapeutics Q4 2025 Earnings Call Insights - Intellectia AI
Akebia Therapeutics Inc reports results for the quarter ended September 30Earnings Summary - TradingView
Akebia Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
AKBA: Vafseo launch drove 50% revenue growth in 2025, with expanding adoption and robust cash reserves - TradingView
Akebia Therapeutics Q4 Earnings Call Highlights - MarketBeat
Akebia Therapeutics Inc (NASDAQ:AKBA) Reports Q4 Revenue Beat and 49% Annual Growth Amid Mixed Market Reaction - ChartMill
Akebia (AKBA) Reports Strong Q4 Revenue and Positive Outlook for Vafseo - GuruFocus
AKEBIA THERAPEUTICS ($AKBA) Releases Q4 2025 Earnings - Quiver Quantitative
Finanzdaten der Akebia Therapeutics Inc-Aktie (AKBA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.75%
1.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):